Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sutezolid - Global Alliance for TB Drug Development/Sequella

Drug Profile

Sutezolid - Global Alliance for TB Drug Development/Sequella

Alternative Names: PF-02341272; PF-2341272; PNU-100480; U 100480; U 101244; U 101603

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator John Hopkins University; Pharmacia Corporation
  • Developer Global Alliance for TB Drug Development; Ludwig-Maximilians-University; Radboud University; Sequella; University of California at San Francisco
  • Class Acetamides; Amides; Antibacterials; Oxazolidinones; Small molecules; Thiamorpholines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Tuberculosis

Most Recent Events

  • 28 Jul 2023 Phase-II/III clinical trials in Tuberculosis (Combination therapy) in South Africa (PO) (NCT05686356)
  • 11 Apr 2023 Radboud University, University of California at San Francisco and University College at London plans a phase II trial (Combination therapy) for Tuberculosis (PO) in Gabon, South Africa, Uganda, Tanzania, Mozambique and Malawi in April 2023 (NCT05807399)
  • 20 Jan 2023 Sequella in collaboration with The Aurum Institute and Global Alliance for TB Drug Development plans a phase II/III trial for Tuberculosis (Combination therapy) in Mozambique, South Africa and Tanzania (NCT05686356)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top